Trials / Recruiting
RecruitingNCT06675357
Using FAPI PET/MRI to Evaluate Prostate Cancer
Novel FAP-targeted Approach to Imaging Patients With or High-risk for Metastatic Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University of Wisconsin, Madison · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | FAPI | 5 +/- 2 mCi of Ga-FAPI-46 |
| PROCEDURE | Positron Emission Tomography (PET) | Undergo PET scan |
| PROCEDURE | Magnetic Resonance Imaging | Undergo MRI scan |
Timeline
- Start date
- 2026-02-27
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2024-11-05
- Last updated
- 2026-03-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06675357. Inclusion in this directory is not an endorsement.